UBS AM
HRMY icon

UBS AM’s Harmony Biosciences HRMY Stock Holding History

UBS AM’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Sell
84,130
-57,410
-41% -$1.81M ﹤0.01% 1871
2026
Q1 		$3.96M Buy
141,540
+1,601
+1% +$52.5K ﹤0.01% 1685
2025
Q4 		$5.24M Buy
139,939
+70,069
+100% +$2.3M ﹤0.01% 1441
2025
Q3 		$1.93M Sell
69,870
-61,254
-47% -$2.11M ﹤0.01% 1769
2025
Q2 		$4.14M Buy
131,124
+35,735
+37% +$1.15M ﹤0.01% 1794
2025
Q1 		$3.17M Buy
95,389
+33,058
+53% +$1.19M ﹤0.01% 1787
2024
Q4 		$2.14M Buy
62,331
+678
+1% +$23.3K ﹤0.01% 2002
2024
Q3 		$2.47M Sell
61,653
-6,719
-10% -$236K ﹤0.01% 1932
2024
Q2 		$2.06M Buy
68,372
+31,593
+86% +$950K ﹤0.01% 1979
2024
Q1 		$1.24M Hold
36,779
– – ﹤0.01% 1909
2023
Q4 		$1.19M Sell
36,779
-1,713
-4% -$47.8K ﹤0.01% 1936
2023
Q3 		$1.26M Buy
38,492
+25,873
+205% +$898K ﹤0.01% 1831
2023
Q2 		$412K Hold
12,619
– – ﹤0.01% 2380
2023
Q1 		$412K Sell
12,619
-18,481
-59% -$842K ﹤0.01% 2380
2022
Q4 		$1.71M Buy
31,100
+6,308
+25% +$347K ﹤0.01% 1597
2022
Q3 		$1.1M Buy
24,792
+7,209
+41% +$352K ﹤0.01% 1909
2022
Q2 		$858K Hold
17,583
– – ﹤0.01% 2052
2022
Q1 		$855K Buy
17,583
+5,559
+46% +$227K ﹤0.01% 2220
2021
Q4 		$513K Buy
+12,024
New +$479K ﹤0.01% 2551

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM's HRMY Position: Q2 2026 in Review

UBS AM reduced its Harmony Biosciences (HRMY) stake by 41% in Q2 2026, selling an estimated $1.81M and leaving 84,130 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

UBS AM first reported a position in HRMY in Q4 2021 and has held it in 19 quarters since. The position peaked at $5.24M in Q4 2025. 326 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • UBS AM held 84,130 shares of Harmony Biosciences worth $3.06M as of Q2 2026.
  • UBS AM sold 57,410 Harmony Biosciences shares in Q2 2026, an estimated $1.81M.
  • Harmony Biosciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1871 holding.
  • UBS AM first reported a position in Harmony Biosciences in Q4 2021 and has held it in 19 quarters since.
  • UBS AM's Harmony Biosciences position peaked at $5.24M in Q4 2025.
  • 326 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.